Medicare and GLP-1s in 2026: What's Covered, What's Not, and the Bridge Program

Medicare has covered almost every injectable medication for diabetes for decades. GLP-1s for obesity? Until July 2026, the answer has been a categorical no — written into federal statute in 2003 and unchanged since. That changes this summer, conditionally, and temporarily.

This guide covers the full picture: the historical exclusion, the new Bridge program, standard Part D's current scope, how to access these drugs as a Medicare beneficiary, and the open question that every patient on this medication should be asking.

Why Medicare Didn't Cover GLP-1s for Weight Loss

The Medicare Modernization Act of 2003 created Part D but also codified a list of excluded drug classes. Weight loss drugs were on it. The statutory language bars coverage of “agents when used for anorexia, weight loss, or weight gain.” That single clause has kept obesity-indicated GLP-1s off every Part D formulary for twenty years.

The exclusion was not written with tirzepatide or semaglutide in mind — those molecules did not exist. It was written for older amphetamine-derivative appetite suppressants. But it has been applied broadly, and Congress has not changed it.

The result: a 65-year-old Medicare beneficiary with a BMI of 40 and hypertension has watched younger colleagues receive full insurance coverage for Wegovy while paying list price themselves, or going without.

What Changed in 2024: Wegovy for Cardiovascular Risk

The first crack appeared in June 2024 when the FDA approved a new indication for Wegovy: reduction of cardiovascular events in adults with obesity or overweight and established cardiovascular disease. The SELECT trial had shown a 20 percent relative reduction in major cardiovascular events.

That approval created a problem for the statutory exclusion. The drug is the same molecule, same dose, same device. But the indication is now cardiovascular — not weight loss.

CMS and Part D sponsors navigated this awkwardly. Some Part D plans now cover Wegovy under the cardiovascular indication. Many do not. Coverage varies by plan and requires prior authorization confirming the cardiovascular indication on the prescription. If you have existing cardiovascular disease (prior heart attack, stroke, or coronary artery disease) and a BMI ≥ 27, it is worth checking your specific plan's formulary at Medicare.gov.

Ozempic (semaglutide) for Type 2 diabetes has always been covered under Part D when prescribed for diabetes management — the indication predates the obesity indication entirely, and no exclusion applies.

The Medicare GLP-1 Bridge: What It Is

The Medicare GLP-1 Bridge is a CMS-administered demonstration program. It launches July 1, 2026 and runs through December 31, 2027. CMS designed it as a bridge to the longer-term BALANCE Model — a voluntary demonstration for Medicare Part D that has since been indefinitely delayed.

The Bridge operates entirely outside the standard Part D benefit structure. Part D sponsors do not need to opt in, and they bear no financial risk for Bridge prescriptions. CMS processes claims through a single central processor — Humana, acting on behalf of CMS — rather than through individual Part D plans.

That separation matters in two directions. First, it means every Part D enrollee who meets clinical criteria can access the Bridge regardless of which plan they hold. Second, it means Bridge costs sit in an accounting silo: your $50 copay does not count toward your Part D deductible, does not accelerate you toward the $2,100 out-of-pocket cap, and does not interact with your plan's formulary in any way.

Covered Medications: The Exact List

The Bridge covers three brands:

• Foundayo — all formulations
• Wegovy — injection pen and tablet formulations
• Zepbound KwikPen — the multi-dose KwikPen form only

Critically, the Zepbound single-dose vial and single-dose pen are not covered. If your prescriber writes for the vial, the Bridge claim will not process. The prescription must specify the KwikPen formulation.

Ozempic is not covered under the Bridge. Mounjaro is not covered. These drugs have no obesity-indicated approval that fits the Bridge's scope; Ozempic and Mounjaro are approved for Type 2 diabetes, not weight reduction.

Who Qualifies: The Three Clinical Pathways

To access the Bridge, a beneficiary must be enrolled in a Medicare Part D plan (standalone PDP or Medicare Advantage with drug coverage) and be at least 18 years old. The prescription must be for the purpose of weight reduction combined with ongoing lifestyle modification — the prescriber attest to that on the prior authorization.

Beyond enrollment, eligibility depends on which of three BMI-plus-condition pathways you meet. For a broader look at how GLP-1 eligibility criteria work across payer types, see our GLP-1 eligibility criteria guide.

Pathway 1 — BMI ≥ 35

No additional diagnosis required. A body mass index of 35 or above, as assessed at the time of initial GLP-1 therapy, qualifies on its own.

Pathway 2 — BMI ≥ 30 plus a qualifying cardiovascular or renal condition

The qualifying conditions are: heart failure with preserved ejection fraction; uncontrolled hypertension (systolic above 140 or diastolic above 90 despite two antihypertensive medications); or chronic kidney disease stage 3a or higher.

Pathway 3 — BMI ≥ 27 plus a qualifying metabolic or vascular condition

The qualifying conditions are: pre-diabetes per American Diabetes Association guidelines; a previous myocardial infarction; a previous stroke; or symptomatic peripheral artery disease.

CMS assesses clinical criteria at the time of initial GLP-1 therapy start, not at the moment of prior authorization submission. If you started a GLP-1 before the Bridge opened and meet these thresholds, your prescriber can attest to that baseline.

The $50 Copay: How the Money Works

The manufacturer net price under the Bridge is $245 per monthly supply — a price CMS negotiated directly with Eli Lilly and Novo Nordisk. Beneficiaries pay $50 of that. CMS reimburses pharmacies at no less than the wholesale acquisition cost, minus the copay, plus a dispensing fee.

The copay is flat and consistent across all Part D benefit phases. It does not change whether you are in the deductible phase, initial coverage, or the catastrophic phase. It is $50 every month regardless of your plan's normal cost-sharing structure.

Two important carve-outs on what the $50 does not do:

First, it does not count toward your Part D out-of-pocket cap. The 2026 cap is $2,100. If you are managing multiple expensive medications and tracking your progress toward catastrophic coverage, Bridge prescriptions do not advance that counter.

Second, Low-Income Subsidy (Extra Help) assistance does not apply to Bridge prescriptions. A beneficiary who qualifies for Extra Help and normally pays $0–$10 per Part D drug will owe the full $50 copay for their GLP-1. This is a meaningful affordability barrier for lower-income Medicare enrollees.

How to Access the Bridge: Step by Step

Step 1 — Confirm Part D enrollment. You must be enrolled in a Part D plan for 2026 — either a standalone Prescription Drug Plan or a Medicare Advantage plan with drug coverage. Original Medicare without Part D does not qualify.

Step 2 — Discuss eligibility with your prescriber. Your provider needs to confirm which of the three BMI/clinical pathways applies to you and document the weight-reduction indication with ongoing lifestyle modification. See our how to get a GLP-1 prescription guide for the full process from first appointment to filled Rx.

Step 3 — Provider submits prior authorization to the central processor. The PA goes to Humana acting as CMS's central processor — not to your Part D plan. Your plan is not involved in this decision. CMS is releasing full operational details for this process; your prescriber's office should check the CMS Medicare GLP-1 Bridge page for current submission procedures.

Step 4 — Fill at a participating pharmacy using the Bridge BIN/PCN. Once approved, pharmacies process the claim using a specific billing identification number for the Bridge — distinct from your normal Part D bin. The pharmacy collects $50 at the counter.

Step 5 — Prescription must specify the correct formulation. For tirzepatide, the prescription must name Zepbound KwikPen specifically. A prescription written for the vial will not process.

What Standard Part D Covers Now

Setting the Bridge aside, the standard Part D landscape for GLP-1s in 2026 looks like this:

Ozempic for Type 2 diabetes: Covered by most Part D plans when prescribed for T2D management. Your plan's formulary tier and prior authorization requirements vary; check Medicare.gov with your specific drug list.

Wegovy for cardiovascular risk reduction: Some plans now cover it under the SELECT trial indication. Requires prior authorization confirming established cardiovascular disease and appropriate BMI. Not universally covered — check your plan's formulary.

Wegovy for obesity alone: Not covered under standard Part D. The statutory exclusion for weight loss drugs still applies. The Bridge is the only pathway to Medicare-covered Wegovy for obesity without the cardiovascular indication.

Zepbound for obesity: Not covered under standard Part D outside the Bridge. Zepbound's FDA approval for obstructive sleep apnea may create a separate coverage pathway for some beneficiaries — check your plan — but the obesity indication remains excluded.

Mounjaro for Type 2 diabetes: Some Part D plans cover it; formulary placement varies widely. In r/medicare discussions, beneficiaries note that plan selection is the critical variable: the same drug can cost $35 on one plan and over $1,000 on another, and plans change their formulary status every January.

What Is Not Covered: Manufacturer Assistance Programs

This is the one that catches Medicare beneficiaries off guard most often.

Manufacturer savings programs — Novo Nordisk's NovoCare, Eli Lilly's LillyDirect, and any co-pay card — are federally prohibited from applying to Medicare beneficiaries. This is not a manufacturer policy choice; it is required by the federal anti-kickback statute as interpreted by the Office of Inspector General.

NovoCare's Wegovy $349/month program explicitly excludes Medicare enrollees. LillyDirect's $299–$449/month tiered pricing for Zepbound explicitly excludes Medicare enrollees. These programs are available to commercially insured or cash-paying patients who are not Medicare beneficiaries.

If you are a Medicare beneficiary who has been using one of these programs, note: it is your Medicare enrollment status, not whether you are actively billing Medicare, that triggers the exclusion. Using a manufacturer assistance program while on Medicare may constitute a federal compliance violation.

The same prohibition applies to GoodRx and other pharmacy discount programs when used in place of Medicare Part D — technically using GoodRx for a drug covered by Part D may be a violation of Medicare rules; speak with your prescriber or a Medicare counselor before substituting cash-pay options.

For beneficiaries who qualify for Extra Help, the State Pharmaceutical Assistance Program (SPAP) in your state may provide supplemental cost assistance for some medications — eligibility and formularies vary by state. For a broader overview of how commercial and Medicaid coverage compares, see our GLP-1 insurance coverage guide.

Comparing the Coverage Pathways

The Cliff: December 31, 2027

The Bridge has a hard end date. What happens on January 1, 2028 is genuinely uncertain.

CMS designed the Bridge as a pathway to the BALANCE Model — a broader voluntary Part D demonstration that would have created permanent coverage for obesity-indicated GLP-1s through Part D plans. The BALANCE Model for Medicare has been indefinitely delayed, with no revised launch date.

KFF's analysis states directly: “At this time, it is uncertain how participating beneficiaries will be able to maintain Medicare coverage of their GLP-1 medication for obesity after the Medicare GLP-1 Bridge ends at the end of 2027.”

For beneficiaries who begin GLP-1 therapy under the Bridge, weight regain after discontinuation is a clinical reality — multiple randomized trials show the majority of lost weight returns within a year of stopping. Beginning a medication that may have no affordable continuation pathway after 18 months is a decision worth discussing explicitly with your prescriber before starting.

Two potential post-Bridge paths exist in theory: Congress could pass legislation removing or modifying the statutory exclusion for obesity drugs; or a future BALANCE Model iteration could launch in 2028 or later. Neither is confirmed.

A Note on the r/medicare Experience

Discussion in Medicare-focused communities reveals a consistent theme: formulary complexity catches people off guard. Medicare beneficiaries navigating GLP-1 coverage report that the same drug can cost $35 on one Part D plan and over $1,000 on another — and plans change their formulary placement every January. One pharmacist posting in r/medicare noted: “I wish I could print this out and give it to every Medicare patient — might save me from getting yelled at multiple times a day, every January, when folks get surprised by changes.”

For GLP-1s specifically, the Bridge changes the calculus: the central-processor model means your specific plan is irrelevant for Bridge access. But for Wegovy under the cardiovascular indication and Ozempic under diabetes, plan selection remains the most important variable, and the Medicare.gov plan comparison tool is the right starting point.

All pricing and program details reflect CMS information as of May 2026. Medicare program parameters can change; verify current details at cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge and medicare.gov. If you are managing multiple Part D medications, compare plans annually at the Medicare.gov plan finder. This article is editorial information, not medical or legal advice; your prescriber determines clinical eligibility.

Internal resources: Zepbound cost guide — Cheapest place to get Wegovy — Wegovy without insurance — GLP-1 savings card guide — LillyDirect Zepbound enrollment